-First-in-Human Phase I study is anticipated to commence in 2021- June 16, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering ...
Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising projections by over $11M. The Korean investment group HLB Co., LTD led ...
-ITI Board adds significant oncology drug development and commercialization expertise to the Board- May 05, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage ...
-Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform- ...
GOLDEN, Colo., April 14, 2020 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free injection system will be used to deliver a COVID-19 vaccine being ...
April 09, 2020 04:00 PM Eastern Daylight Time ROCKVILLE, Md. & PROVIDENCE, R.I. & GOLDEN, Colo.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study ...
- Meeting on ITI-1001 Phase I program for treatment of Newly-Diagnosed Glioblastoma (GBM) - March 03, 2020 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held ...
Nov. 20, 2019 ROCKVILLE, MD – Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that Duane Mitchell, MD, ...
November 04, 2019 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that ...
- ITI-1000 targets CMV with Immunomic Therapeutics’ immunotherapy UNITE™ platform - ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) ...
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. ...
July 12, 2019 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as ...